Chemoinformaics analysis of 14-Oxotricosanoic acid
| Molecular Weight | 368.602 | nRot | 21 |
| Heavy Atom Molecular Weight | 324.25 | nRig | 1 |
| Exact Molecular Weight | 368.329 | nRing | 0 |
| Solubility: LogS | -1.35 | nHRing | 0 |
| Solubility: LogP | 1.556 | No. of Aliphatic Rings | 0 |
| Acid Count | 1 | No. of Aromatic Rings | 0 |
| Base Count | 0 | No. of Aliphatic Carbocycles Rings | 0 |
| Atoms Count | 70 | No. of Aliphatic Hetero Cycles | 0 |
| No. of Heavy Atom | 26 | No. of Aromatic Carbocycles | 0 |
| nHetero | 3 | No. of Aromatic Hetero Cycles | 0 |
| nBridge Head | 0 | No. Saturated Carbocycles | 0 |
| No. of Hydrogen atom | 44 | No. of Saturated Hetero Cycles | 0 |
| No. of Carbon atom | 23 | No. of Saturated Rings | 0 |
| No. of Nitrogen atom | 0 | No. of Arom Atom | 0 |
| No. of Oxygen atom | 3 | No. of Arom Bond | 0 |
| nHA | 2 | APOL | 70.1549 |
| nHD | 1 | BPOL | 45.8771 |
| QED | 0.507 |
| Synth | 2.294 |
| Natural Product Likeliness | 0.674 |
| NR-PPAR-gamma | 0.002 |
| Lipinski | Accepted |
| Pfizer | Accepted |
| GSK | Accepted |
| Golden Triangle | Rejected |
| Pgp-inh | 0.001 |
| Pgp-sub | 0.003 |
| HIA | 0.003 |
| CACO-2 | -4.227 |
| MDCK | 0.0000274 |
| BBB | 0.993 |
| PPB | 0.178411 |
| VDSS | 1.047 |
| FU | 0.836018 |
| CYP1A2-inh | 0.722 |
| CYP1A2-sub | 0.826 |
| CYP2c19-inh | 0.192 |
| CYP2c19-sub | 0.875 |
| CYP2c9-inh | 0.023 |
| CYP2c9-sub | 0.223 |
| CYP2d6-inh | 0.012 |
| CYP2d6-sub | 0.439 |
| CYP3a4-inh | 0.021 |
| CYP3a4-sub | 0.374 |
| CL | 9.106 |
| T12 | 0.779 |
| hERG | 0.014 |
| Ames | 0.014 |
| ROA | 0.054 |
| SkinSen | 0.353 |
| Carcinogencity | 0.058 |
| EI | 0.984 |
| Respiratory | 0.414 |
| NR-Aromatase | 0.006 |
| Antiviral | No |
| Prediction | 0.537149 |